Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4452-4461

  Miller, Todd W ^a   Balko, Justin M ^a   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ANASTROZOLE; ANTIESTROGEN; BGT 226; BKM 120; BYL 719; CAL 101; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FULVESTRANT; GDC 0032; GDC 0980; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PF 4691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 587; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 147; XL 765;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL ACTIVATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; DISEASE FREE SURVIVAL; DNA MODIFICATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 81755162797     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.4879     Document Type: Review

References (124)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Forbes JF, Cuzick J, Buzdar A, et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
3. Ellis MJ, Tao Y, Young O, et al.: Estrogenindependent proliferation is present in estrogenreceptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019-3025, 2006 (Pubitemid 46638935)
4. Arpino G, Green SJ, Allred DC, et al.: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. Clin Cancer Res 10:5670-5676, 2004 (Pubitemid 39180941)
5. De Laurentiis M, Arpino G, Massarelli E, et al.: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748, 2005 (Pubitemid 41557193)
6. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
7. Shou J, Massarweh S, Osborne CK, et al.: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2- positive breast cancer. J Natl Cancer Inst 96:926-935, 2004 (Pubitemid 38868139)
8. Bartlett JMS, Brookes CL, van de Velde CJH, et al.: Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the TEAM pathology substudy. Cancer Res 70, 2010 (abstr S2-4)
9. Robertson JF, Llombart-Cussac A, Rolski J, et al.: Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study. J Clin Oncol 27:4530-4535, 2009
10. Robertson JFR, Dixon JM, Sibbering DM, et al.: Tumor biomarker changes following pre-surgical treatment with 500 mg fulvestrant plus anastrozole versus 500 mg fulvestrant alone and 1 mg anastrozole alone. Cancer Res 69, 2009 (abstr 24)
11. Robertson JFR, Lindemann JPO, Llombart- Cussac A, et al.: A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the "FIRST"study. Cancer Res 70, 2010 (abstr S1-3)
12. Pérez-Tenorio G, Alkhori L, Olsson B, et al.: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13:3577-3584, 2007 (Pubitemid 46955118)
13. Saal LH, Johansson P, Holm K, et al.: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104:7564-7569, 2007 (Pubitemid 47185946)
14. Shoman N, Klassen S, McFadden A, et al.: Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18:250-259, 2005 (Pubitemid 40188633)
15. Baselga J, Semiglazov V, van Dam P, et al.: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009
16. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al.: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091, 2008
17. Ellis MJ, Lin L, Crowder R, et al.: Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119:379-390, 2010
18. Campbell IG, Russell SE, Choong DY, et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678-7681, 2004 (Pubitemid 39446895)
19. Crowder RJ, Phommaly C, Tao Y, et al.: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69:3955-3962, 2009
20. Law JH, Habibi G, Hu K, et al.: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246, 2008
21. Turner N, Pearson A, Sharpe R, et al.: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085-2094, 2010
22. Monni O, Barlund M, Mousses S, et al.: Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A 98:5711-5716, 2001 (Pubitemid 32435707)
23. Gewinner C, Wang ZC, Richardson A, et al.: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16:115-125, 2009
24. Fedele CG, Ooms LM, Ho M, et al.: Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A 107:22231-22236, 2010
25. Jaiswal BS, Janakiraman V, Kljavin NM, et al.: Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16:463-474, 2009
26. Loi S, Haibe-Kains B, Majjaj S, et al.: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107:10208-10213, 2010
27. Carpten JD, Faber AL, Horn C, et al.: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444, 2007 (Pubitemid 47123510)
28. Bellacosa A, de Feo D, Godwin AK, et al.: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280-285, 1995
29. Al-Kuraya K, Schraml P, Torhorst J, et al.: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540, 2004 (Pubitemid 39552065)
30. Maurer M, Su T, Saal LH, et al.: 3- phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 69:6299-6306, 2009
31. Rochlitz CF, Scott GK, Dodson JM, et al.: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49:357-360, 1989 (Pubitemid 19049527)
32. Di Nicolantonio F, Arena S, Tabernero J, et al.: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120:2858-2866, 2010
33. Whitman M, Downes CP, Keeler M, et al.: Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332:644-646, 1988
34. Anderson KE, Coadwell J, Stephens LR, et al.: Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr Biol 8:684-691, 1998 (Pubitemid 28286275)
35. Franke TF, Yang SI, Chan TO, et al.: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736, 1995
36. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378, 1998
37. Gingras AC, Kennedy SG, O'Leary MA, et al.: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12:502-513, 1998
38. Sarbassov DD, Ali SM, Kim DH, et al.: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004 (Pubitemid 38991819)
39. Campbell RA, Bhat-Nakshatri P, Patel NM, et al.: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276:9817-9824, 2001
40. Yamnik RL, Digilova A, Davis DC, et al.: S6 kinase 1 regulates estrogen receptor alpha in controlof breast cancer cell proliferation. J Biol Chem 284:6361-6369, 2009
41. Coso OA, Chiariello M, Yu JC, et al.: The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81:1137-1146, 1995
42. Minden A, Lin A, Claret FX, et al.: Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147-1157, 1995
43. Logan SK, Falasca M, Hu P, et al.: Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. Mol Cell Biol 17:5784- 5790, 1997
44. Hibi M, Lin A, Smeal T, et al.: Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135-2148, 1993 (Pubitemid 23336140)
45. Derijard B, Hibi M, Wu IH, et al.: JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037, 1994 (Pubitemid 24106383)
46. Rauscher FJ 3rd, Cohen DR, Curran T, et al.: Fos-associated protein p39 is the product of the jun proto-oncogene. Science 240:1010-1016, 1988
47. DeNardo DG, Cuba VL, Kim H, et al.: Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol 277:13-25, 2007 (Pubitemid 47488609)
48. Petz LN, Ziegler YS, Loven MA, et al.: Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 143:4583-4591, 2002 (Pubitemid 35397599)
49. Massarweh S, Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities. Clin Cancer Res 13:1950-1954, 2007 (Pubitemid 46649859)
50. Generali D, Fox SB, Brizzi MP, et al.: Downregulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 14:2673-2680, 2008
51. Miller TW, Perez-Torres M, Narasanna A, et al.: Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69:4192-4201, 2009
52. Massarweh S, Osborne CK, Creighton CJ, et al.: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833, 2008 (Pubitemid 351206760)
53. Sabnis G, Schayowitz A, Goloubeva O, et al.: Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 69:1416-1428, 2009
54. Wang X, Masri S, Phung S, et al.: The role of amphiregulin in exemestane-resistant breast cancer cells: Evidence of an autocrine loop. Cancer Res 68:2259-2265, 2008 (Pubitemid 351521799)
55. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al.: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120:2406-2413, 2010
56. Fan M, Yan PS, Hartman-Frey C, et al.: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954-11966, 2006 (Pubitemid 46094209)
57. Frogne T, Benjaminsen RV, Sonne-Hansen K, et al.: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114:263-275, 2009
58. Massarweh S, Osborne CK, Jiang S, et al.: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66:8266-8273, 2006 (Pubitemid 44299196)
59. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al.: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541, 2000
60. Song RX, McPherson RA, Adam L, et al.: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16:116-127, 2002 (Pubitemid 34044502)
61. Song RX, Fan P, Yue W, et al.: Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr Relat Cancer 13:S3-S13, 2006 (suppl 1)
62. Wang Z, Zhang X, Shen P, et al.: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103:9063-9068, 2006 (Pubitemid 43902533)
63. Li L, Haynes MP, Bender JR: Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 100:4807-4812, 2003 (Pubitemid 36457810)
64. Filardo EJ, Quinn JA, Bland KI, et al.: Estrogeninduced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649-1660, 2000
65. Pedram A, Razandi M, Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20:1996-2009, 2006 (Pubitemid 44286700)
66. Voliva CF, Pecchi S, Burger M, et al.: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in phase I/II clinical trials. Cancer Res 70, 2010 (abstr 4498)
67. Sabnis G, Goloubeva O, Jelovac D, et al.: Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogendeprived breast cancer xenografts to antiestrogens. Clin Cancer Res 13:2751-2757, 2007
68. Yue W, Wang J, Li Y, et al.: Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer 117:746-754, 2005 (Pubitemid 41598825)
69. Meyer DS, Brinkhaus H, Muller U, et al.: Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 71:4344-4351, 2011
70. Zhao L, Vogt PK: Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 105:2652-2657, 2008 (Pubitemid 351520568)
71. Isakoff SJ, Engelman JA, Irie HY, et al.: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65:10992-11000, 2005 (Pubitemid 41713369)
72. Samuels Y, Wang Z, Bardelli A, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004 (Pubitemid 38541907)
73. Janku F, Tsimberidou AM, Garrido-Laguna I, et al.: PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Mol Cancer Ther 10:558-565, 2011
74. Miron A, Varadi M, Carrasco D, et al.: PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70:5674-5678, 2011
75. Dupont Jensen J, Laenkholm AV, Knoop A, et al.: PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17:667-677, 2011
76. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al.: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10:1093-1101, 2011
77. Creighton CJ, Fu X, Hennessy BT, et al.: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12:R40, 2010
78. Sørlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
79. Bachelot T, Bourgier C, Cropet C, et al.: TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormonereceptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 70, 2010 (abstr S1-6)
80. Miller TW, Forbes JT, Shah C, et al.: Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15:7266-7276, 2009
81. O'Reilly KE, Rojo F, She QB, et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006 (Pubitemid 43259931)
82. Carracedo A, Ma L, Teruya-Feldstein J, et al.: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065-3074, 2008
83. Chakrabarty A, Sánchez V, Kuba MG, et al.: Breast cancer special feature: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A [epub ahead of print on February 28, 2011]
84. Chandarlapaty S, Sawai A, Scaltriti M, et al.: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
85. Garrett JT, Olivares MG, Rinehart C, et al.: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021-5026, 2011
86. Amin DN, Sergina N, Ahuja D, et al.: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2:16ra7, 2011
87. Lipton A, Ali SM, Leitzel K, et al.: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21:1967-1972, 2003 (Pubitemid 46606385)
88. Arpino G, Wiechmann L, Osborne CK, et al.: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29:217-233, 2008 (Pubitemid 351519691)
89. Benz CC, Scott GK, Sarup JC, et al.: Estrogendependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1992 (Pubitemid 23063891)
90. Pietras RJ, Arboleda J, Reese DM, et al.: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
91. Gutierrez MC, Detre S, Johnston S, et al.: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476, 2005 (Pubitemid 47050837)
92. Xia W, Bacus S, Hegde P, et al.: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103:7795-7800, 2006
93. Munzone E, Curigliano G, Rocca A, et al.: Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:R4, 2006
94. Johnston S, Pippen J Jr, Pivot X, et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
95. Kaufman B, Mackey JR, Clemens MR, et al.: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
96. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619, 2006 (Pubitemid 44100518)
97. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296:1655-1657, 2002
98. Vanhaesebroeck B, Leevers SJ, Panayotou G, et al.: Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem Sci 22:267-272, 1997 (Pubitemid 27310948)
99. Jia S, Roberts TM, Zhao JJ: Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21:199-208, 2009
100. Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27:5511-5526, 2008
101. Maira SM, Voliva C, Garcia-Echeverria C: Class IA phosphatidylinositol 3-kinase: From their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 12:223-238, 2008 (Pubitemid 351284964)
102. Maira SM, Stauffer F, Brueggen J, et al.: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-1863, 2008
103. Garlich JR, De P, Dey N, et al.: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68:206-215, 2008
104. Folkes AJ, Ahmadi K, Alderton WK, et al.: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin- 1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51:5522-5532, 2008
105. Furman RR, Byrd JC, Flinn IW, et al.: Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 28:241s, 2010 (suppl; abstr 3032)
106. Baselga J, De Jonge MJ, Rodon J, et al.: A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 28:233s, 2010 (suppl; abstr 3003)
107. Burris H, Rodon J, Sharma S, et al.: First-inhuman phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 28:234s, 2010 (suppl; abstr 3005)
108. Edelman G, Bedell C, Shapiro G, et al.: A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 28:234s, 2010 (suppl; abstr 3004)
109. Rhodes N, Heerding DA, Duckett DR, et al.: Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68:2366-2374, 2008 (Pubitemid 351521811)
110. Davies TG, Verdonk ML, Graham B, et al.: A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol 367:882-894, 2007 (Pubitemid 46335912)
111. Toral-Barza L, Zhang WG, Huang X, et al.: Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: Mechanistic involvement of AKT catalytic activation loop cysteines. Mol Cancer Ther 6:3028- 3038, 2007
112. She QB, Chandarlapaty S, Ye Q, et al.: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3:e3065, 2008
113. Yap TA, Yan L, Patnaik A, et al.: Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. J Clin Oncol 29: 194s, 2011 (suppl; abstr 3001)
114. Biondo A, Yap TA, Yan L, et al.: Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 29:203s, 2011 (suppl; abstr 3037)
115. Fasolo A, Sessa C: MTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 17:1717-1734, 2008
116. Stuart D, Sellers WR: Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol 21:304-310, 2009
117. Dowsett M, Smith IE, Ebbs SR, et al.: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
118. Ellis MJ, Tao Y, Luo J, et al.: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380- 1388, 2008
119. Ellis PA, Smith IE, Detre S, et al.: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48:107-116, 1998 (Pubitemid 28156355)
120. Assersohn L, Salter J, Powles TJ, et al.: Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82:113-123, 2003 (Pubitemid 37476011)
121. Smith IE, Walsh G, Skene A, et al.: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816-3822, 2007 (Pubitemid 47477255)
122. Cristofanilli M, Valero V, Mangalik A, et al.: Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16:1904-1914, 2010
123. Johnston SR, Semiglazov VF, Manikhas GM, et al.: A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 110:327-335, 2008 (Pubitemid 351793882)
124. Kaufman PA, Ferrero JM, Bourgeois H, et al.: A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 70, 2010 (abstr S1-4)